Research And Development Tenders

Open House Discount Drug Contracts Peginterferon Beta-1A, Atc L03ab13

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Substance Certolizumab Pegol, Atc L04ab055 for the Period August 1St, 2023 - July 31St, 2025

Open House Drug Discount Agreements Tolvaptan, Atc C03xa01 And/Or Atc G04bx21

Open House Drug Rebate Contracts Formoterol, Glycopyrronium Bromide and Beclometasone, Atc R03al09

Conclusion of a Non-Exclusive Discount Agreement in Accordance with § 130A Paragraph 8 Sgb V for the Active Substance Melatonin (Exclusively in the Potency 2 Mg), Atc N05ch01 for the Period August 1St, 2023 - July 31St, 2025

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Substance Iron(Iii) Derisomaltose, Atc B03ac08 for the Period August 1St, 2023 - July 31St, 2025

Conclusion of a Non-Exclusive Discount Agreement According to Section 130A Paragraph 8 Sgb V for the Active Substance Tranexamic Acid (Exclusively Oral Dosage Forms), Atc B02aa02 for the Period August 1St, 2023 - July 31St, 2025

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Substance Nilotinib, Atc L01ea03 for the Period August 1St, 2023 - July 31St, 2025

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Ingredient Fluorouracil, Atc D11af05 for the Period August 1St, 2023 - July 31St, 2025

Open House Drug Rebate Contracts Permethrin, Atc P03ac04